Macrolide Therapy for Chlamydia pneumoniae in the Secondary Prevention of Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials

Pharmacotherapy

Volumn 24, Issue 3, 2004, Pages 338-343

  Etminan, Mahyar ^a,b   Carleton, Bruce ^c   Delaney, J A C ^a   Padwal, Raj ^d,e  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antibiotics; Chlamydia pneumoniae; Coronary disease; Meta analysis; Myocardial infarction

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE; PLACEBO; ROXITHROMYCIN;

ANGINA PECTORIS; ANTIBIOTIC THERAPY; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; EMBASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; Q STATISTIC; RANDOM EFFECTS MODEL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; STATISTICAL MODEL;

ANTIBIOTIC PROPHYLAXIS; CANADA; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERIOSCLEROSIS; HUMANS; MACROLIDES; PNEUMONIA, BACTERIAL; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

EID: 1542376230     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.4.338.33181     Document Type: Review

References (33)

1. American Heart Association. 2003 heart and stroke statistical update. Dallas, TX: American Heart Association, 2003.
2. Braunwald E. Cardiovascular medicine at the turn of the millennium: triumphs, concerns and opportunities. N Engl J Med 1997;337:1360-9.
3. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 1997;277:535-42.
4. Libby P, Egan D, Skarlatos S. Role of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96:4095-103.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
6. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002;288:2724-31.
7. Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 2000;321:208-13.
8. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000;102:1755-60.
9. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999;20:121-7.
10. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 2000;356:1228-31.
11. Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 1999;150:206-15.
12. Costa-Bouzas J, Takkouche B, Cadarso-Suarez C, Spiegelman D. HEpiMA: software for the identification of heterogeneity in meta-analysis. Comput Methods Programs Biomed 2001;64:101-7.
13. Cercek B, Shah PK, Noc M, et al. The effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndromes. Lancet 2001;361:809-13.
14. O'Connor MC, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary artery disease events. The WIZARD study: a randomized controlled trial. JAMA 2003;290:1459-66.
15. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the azithromycin in coronary artery disease: elimination of myocardial infection with chlamydia (ACADEMIC) study. Circulation 1999;99:1540-7.
16. Gurfinkel E, Bozovich G, Daroc A, Beck E, Mautner B. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study: ROXIS study group. Lancet 1997;350:404-7.
17. Leowattana W, Bhuripanyo K, Singhaviranon L, et al. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai 2001: 84(suppl 3):S669-75.
18. Sinisalo J, Mattila K, Valtonen V, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. The clarithromycin in acute coronary syndrome patients in Finland (CLARIFY) study group. Circulation 2002;105:1555-60.
19. Stone AF, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA). Circulation 2002;106:1219-23.
20. Zahn R, Schneider S, Frilling B. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 2003;107:1253-9.
21. Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomized, double-blind, placebo-controlled trial. Lancet 2001;357:2085-9.
22. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996;64:1614-20.
23. Godzik KL, O'Brien ER, Wang SK, Kuo CC. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 1995;33:2411-14.
24. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog 1996;21:215-21.
25. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998;177:725-9.
26. Kaukoranta-Tolvanen SS, Ronni T, Leinonen M, Saikku P, Laitinen K. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb Pathog 1996;21:407-11.
27. Liuba P, Karnani P, Pesonen E, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation 2000;102:1039-44.
28. Netea MG, Selzman CH, Kullberg BJ, et al. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol 2000;30:541-9.
29. Coombes BK, Mahony JB. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infect Immun 1999;67:2909-15.
30. Kol A, Suchova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998;98:300-7.
31. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002;89:860-1.
32. Jackson LA. Description and status of the azithromycin and coronary events study (ACES). J Infect Dis 2000;181:S579-81.
33. Hansen S, Als-Nielsen B, Damgaard M, Helo OH, Petersen L, Jespersen CM. Intervention with clarithromycin in patients with stable coronary heart disease. Heart Drug 2001;1:14-19.